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Introduction
The occurrence of rheumatoid arthritis (RA) is
strongly associated with the expression of particular human
leukocyte antigen (HLA) class II alleles in several racial
groups bearing the third hypervariable region shared epi-
tope sequence, 67-74:LLEQKRAA.1-3 In Caucasians, RA-
related subtypes of DR1 and DR4 occur more frequently
than the subtypes of DR10 or DR144.5 A DR4-DQ3 associ-
ation has been reported in Indian RA patients6, whereas an
increased frequency of DR1 and DR10 has been found to be
in RA patients from other population groups.7-9 All these
studies indicate that the association of a particular allele
with RA varies among different races and it would be
important to study the frequencies of DR and DQ alleles in
Pakistani RA patients.
Moreover, association between a particular allele of
HLA-DR in RA patients and clinical response to methotrex-
ate (MTX) has also been a subject of great interest among
rheumatologists due to the well documented short-term effi-
cacy of this drug in the treatment of refractory RA.10-13 In
one study, HLA-DR2 was found to be associated with a
good response to MTX, while another study, reported a lack
of association between HLA-DR2 and substantial clinical
response to MTX.11,14
The present study was undertaken to investigate the
frequency and distribution of DRB1 and DQB1 alleles in a
hospital based Pakistani population of RA patients and to
analyze the relationship between clinical response to MTX
and the HLA-DR and HLA-DQ genotypes in these patients.
Patients and Methods
Ninety one  RA patients (16 males and 75 females)
visiting the Rheumatology Clinic at the Aga Khan
University (June 1998 to June 2000) and A.O. Clinic,
Karachi, were selected randomly for this study. All the
patients fulfilled the diagnostic criteria of the American
Rheumatism Association for RA. Their mean SD age was
43.4 3 years.  Majority (87%) of patients were rheumatoid
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Abstract
Objective: To investigate the frequency and distribution of DRB1 and DQB1 alleles in Patients with rheumatoid
arthritis (RA) and  analyze the relationship between clinical response to methotrexate  (MTX) and the HLA-DR
and HLA-DQ genotypes in these patients.
Methods: In this case-control study, the HLA-DRB1 and HLA-DQB1 polymorphism in 91 RA patients and 91
healthy controls was done using polymerase chain reaction and sequence specific primers.
Results: There was no statistical difference in frequencies of HLA-DRB1*03, DRB1*04, DRB1*07, DRB1*10,
DRB1*11, DRB1*12, DRB1*13, DRB1*14, DRB1*15 and DRB1*16 genotypes between patients and controls.
However, DRB1*01 was found to be significantly more common (p=0.015) in RA patients compared to controls.
HLA-DRB1*15 was more common in patients (43.5%) compared to controls (30.8%) but results were not signif-
icant.  HLA-DRB1*08 and DRB1*09 were present in negligible number in patients as well as controls while HLA-
DRB1*12 was conspicuously absent in controls.  Similarly, DQB1*06 was also significantly more common (p =
0.01) among the patients compared to healthy control subjects, while there was no statistical difference in the
frequencies of DQB1*02, DQB1*03, DQB1*04 and DQB1*05 among the cases and the controls. RA susceptibil-
ity in most patients appeared to be associated with the HLA-DRB1*01/DQB1*06 genotype.  Regarding associa-
tion between HLA-DR or HLA-DQ genotype and clinical response to methotrexate (MTX), the data showed that
with the exception of HLA-DRB1*03, there appears to be no association between the particular subtypes of HLA-
DR and HLA-DQ. HLA-DRB1*03 was significantly more common among non-responders to MTX alluding to the
possibility that another genes responsible for MTX metabolism, might be in linkage disequilibrium with HLA-
DRB1*03 in the Pakistani population, thereby making such individuals non-responsive to MTX-therapy.
Conclusion: RA susceptibility in most Pakistani patients is associated with the HLA-DRB1*01/DQB1*06 geno-
type.  HLA-DRB1*03 was found to be significantly more common among non-responders to MTX treatment sug-
gesting that Pakistani patients with this genotype are less likely to benefit from MTX (JPMA 56:452;2006).
factor positive.  They belonged to all the major eth-
nic groups of the country and all had been receiving MTX
for at least 6 months and were assessed clinically every
month. Clinical response to MTX was assessed according
to the criteria described by O'Dell et al.15 After 12-24
weeks of treatment with MTX, those showing 50% or more
reduction in ESR, Richie index, number of swollen joints
and morning stiffness as compared to index at entry were
classified as "responders", while those showing little
improvement in these parameters were called 'non-respon-
ders'.
Equal number of controls were randomly selected
from a pool of healthy individuals who had their HLA typ-
ing done for organ donation and represented all the major
ethnic groups in Pakistan. Their mean   SD age was 38.5 +
8.3 years. Controls were free from any chronic illness as
revealed by their clinical examination and biochemical
tests.  Informed consent was obtained from the participants
and the study was approved by the Ethics Review
Committee of the Aga Khan University.
Blood samples (5 ml each) of these patients and con-
trols were obtained in tubes containing EDTA as anticoagu-
lant. White blood cells were separated on Ficoll/Hypaque
and DNA was extracted according to Miller et al.16
Briefly, white blood cells collected in 300  l TE
buffer (10 mM Tris. 1mM EDTA, pH 7.4) were homoge-
nized using a plastic hand homogenizer and incubated at
65oC for 30 minutes after adding 20 µl proteinase-K (10
mg/ml) and 80  µl of 10% SDS. Then, 100  µl of 6 M NaCl
and 10 µl of N-cetyl, N.N. N-trimethyl ammonium bromide
(CTAB) were added and an additional incubation at 65oC
was carried out for 20 minutes. This was followed by addi-
tion of 720 µl of chloroform: isoamylalcohol (24:1) mixture
and centrifuged at 12000 g for 15 minutes. The upper layer
was removed and DNA was precipitated from it using iso-
propanol. Finally, after washing with 70% ethanol, DNA
pellet was resuspended in 50 - 100 µl TE buffer, pH 7.4 and
stored at -70oC until analysis.
HLA-DRB1 and DQB1 genotyping was performed
by the Dynal AllSetTM PCR-SSP low resolution typing kits
according to the manufacturer's instructions (Dynal, UK). A
typical PCR-SSP reaction consisted of 1 X PCR buffer, 200
µM deoxyribonucleotide triphosphate, 5% glycerol,
sequence specific primers, 0.4 unit Taq polymerase and 100
ng extracted DNA in a final volume of 10 µl. After thermal
cycling the amplified products were separated by elec-
trophoresis on a 2% agarose gel, stained with ethidium bro-
mide and photographed under UV illumination. A set of 9
primer pairs was used for HLA-DQ1 typing, while a set of
24 primer pairs was used for DRB1 typing, respectively.
Statistical evaluation was performed using Statistica
for Windows (version 5.0 statsoft, Inc, USA). Descriptive
analysis was carried out for patient's demographic and clin-
ical data, whereas the frequencies of HLA-DRB1 and
DQB1 alleles were compared among responders, non-
responders and control subjects and calculated using the
Chi-square test with Yates correction.  For all tests, a two-
tailed p-value of < 0.05 was considered to be significant.
Results
HLA class-II typing by PCR was performed on a
group of 91 RA patients and 91 healthy subjects. All the
patients were diganosed to have an active PA on the basis of
clinical and laboratory findings. Table 1 shows patients'
clinical and demographic characteristics. The patients
group comprised of 75 females and 16 males with a female
to male ratio of 4.6:1. The mean age was 43 years with a
range between 19-65 years. More than 50% of the patients
had moderate disease, whereas 30% demonstrated severe
type of arthritis and the rest of the patients were classified
under mild disease by ARA criteria. The mean   SD duration
of illness was 7.03 + 4.48 years. The rheumatoid factor was
positive in 87% of the patients.
The distribution of HLA- DRB1 and HLA-DQB1
genotypes in controls and patients is shown in Table 2. HLA-
DRB1*03, HLA-DRB1*07, HLA-DRB1*10, HLA-
DRB1*11 and HLA-DRB1*15 were the most common
HLA-DRB1 genotypes identified in the control group,
whereas HLA-DRB1*01, HLA-DRB1*03, HLA-DRB1*07,
HLA-DRB1*10, HLA-DRB1*11, HLA-DRB1*13 and
HLA-DRB1*15 were the commonest genotypes in the
patient group. HLA-DRB1*01 was  significantly more com-
mon (P=0.015) in patient group compared to the control
group.  The frequency of HLA-DRB*04 was similar in both
control and patient groups.   HLA-DRB1*15 was more com-
mon among patients (43.5%) than the control subjects
(30.8%), however, the frequency values were not statistical-
ly significant.  The study demonstrated that HLA- DQB1*06
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Variable Frequency (%)
Gender 
Age (mean   SD years)
Duration of illness (mean SD years)
Severity of the disease 
Rheumatoid factor
Males
Females
Mild
Moderate
Severe
Positive
Negative
16(17.8)
75 (82.2)
43.4 ± 11 years
7.03  + 4.48
12 (13)
52 (57)
27 (30)
79 (87)
12 (13)
Table 1. Demographic and clinical characteristics of patients with
rheumatoid arthritis.
was significantly (P = 0.01) more common in the
patient group compared to the controls (51.1% vs 33.0%).
The frequency of HLA-DQB1*05 was very high among
controls (52.7%) compared to patients (38%), but the differ-
ence was not statistically significant.  HLA-DRB1*08 and
HLA-DRB1*09 were present in a negligible number (1.1%)
in both patient and control groups.  HLA-DRB1*12 and
HLA-DQB1*04 were conspicuously absent in our normal
population, while these values present in patients (5.4% and
4.3%, respectively).
The distribution of HLA-DRB1 and DQB1 geno-
types in patients who responded to MTX treatment was
compared with the genotypes in patients showing no
response to MTX (Table 3). HLA-DRB1*03 was found to
be significantly (P=0.004) more common among non-
responders (37.2%) compared to responders (14.3%).  In
both the groups, HLA DRB1*15 was the most frequent
genotype. It was present in 46.5% of the non-responders and
in 40.8% of the responders. However, the difference was not
significant.  Similarly, HLA-DQB1*06 also appeared to be
more common among the non-responders compared to
responders (55.8% vs 46.9%), but the difference was not
statistically significant.
Discussion
The association of HLA antigens with RA has been
well characterized and documented in the literature.3,4,8,17
We have carried out this study to examine whether variable
response to MTX observed in RA patients was associated
with HLA-DR or DQ genotypes. 
Depending upon geographical location, HLA-DR
associations with RA vary from population to population.
For example, HLA-DR1 is strongly associated with RA in
Greeks18 generally the frequency of HLA-DR4 is excep-
tionally high among RA patients of other European
Caucasian populations.8 Similarly, in certain South Asian
countries, including India, HLA-DR4 was reported in the
majority of RA patients.19,20 In contrast to these studies,
HLA-DR4 frequency was not significantly different
between the control and patient groups in our study.
However, strong association of RA with HLA-DRB1*01
observed in this study is in line with the findings of
Constantinidou et al.18 who have also reported association
of this genotype with RA in Greek population.  With the
exception of HLA-DRB1*03, patients who demonstrated
good response to MTX treatment failed to show any signif-
icant association with HLA-DR types at the level of resolu-
tion of this study. HLA-DRB1*03 genotype, however, was
found to be significantly more common among non-respon-
ders, indicating influence of genotype in response to MTX
treatment.
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Table 2.  Distribution of HLA-DRB1 and HLA-DQB1 genotypes in
patients with rheumatoid arthritis versus the distribution in normal
healthy control subjects.
HLA
genotype
No. (%)
Controls 
(n=91)
No. (%)
Patients 
(n=91)
p - value
HLA-DRB1
*01
*03
*04
*07
*08
*09
*10
*11
*12
*13
*14
*15
*16
HLA-DQB1
*02
*03
*04
*05
*06
6 (6.6)
27 (29.7)
9 (9.9)
24 (26.3)
1 (1.1)
1 (1.1)
17 (18.7)
19 (20.9)
0 (0)
11 (12.1)
13 (14.3)
28 (30.8)
7 (7.6)
41 (45)
33 (36.3)
0 (0)
48 (52.7)
30 (33)
17 (18.5)
25 (27.5)
10 (10.9)
16 (17.4)
1 1.1)
1 (1.1)
16 (17.4)
13 (14.4)
5 (5.4)
18 (19.6)
10 (10.9)
40 (43.5)
5 (5.5)
39 (42.4)
29 (31.5)
4 (4.3)
35 (38)
47 (51.1)
0.015*
NS
NS
NS
NS
NS
NS
NS
-
NS
NS
NS
NS
NS
NS
NS
NS
0.01**
*Yates corrected p-value=0.025; Odds ratio=3.25; 95% C.I. (1.13-9.8)
**Yates corrected p-value=0.016; Odds ratio=2.17; 95% C.I. (1.14-4.14)
NS= Not significant
Table 3.  Distribution of HLA-DRB1 and DQB1 genotypes in patients
with rheumatoid arthritis who responded to treatment with
methotrexate and in those who did not respond to this treatment.
HLA
genotype
No. (%) No. (%)
P-valueResponders 
(n=48)
Non - responders 
(n=43)
HLA-DRB1
*01
*03
*04
*07
*08
*09
*10
*11
*12
*13
*14
*15
*16
HLA-DQB1
*02
*03
*04
*05
*06
6(12.2)
7(14.3)
8 (16.3)
12(24.5)
-
-
10 (20.4)
10 (20.4)
2(4.1)
9 (18.4)
7 (14.3)
20 (40.8)
3 (6.1)
20 (40.8)
17 (34.7)
4 (8.2)
21 (42.9)
23 (46.9)
6 (14)
18 (37.2)
2 (4.7)
4 (9.3)
1(2.3)
1(2.3)
6 (14)
3 (7)
3 (7)
9 (20.9)
3(7)
20 (46.5)
2(4.7)
19 (44.2)
12 (27.9)
-
14 (32.6)
24 (55.8)
NS
0.004*
NS
NS
-
-
NS
NS
NS
NS
NS
NS
NS
NS
NS
-
NS
NS
NS = Not significant
*Yates corrected p-value=0.007; Odds ratio=4.22; 95% C.I. (1.4-13.1)
Our data showed non-significant but increased fre-
quency of HLA-DRB1*15 in RA patients of Pakistani ori-
gin. This is in sharp contrast to the findings of Taneja et al.19
who have reported a decreased frequency of HLA-
DRB1*15 in Indian patients compared to RA- free controls.
Similar to our findings, Hameed et al.21 have also shown an
increased frequency of HLA-DR2 in RA patients compared
to healthy controls (33.1% vs 19%) but the difference was
not statistically significant (P= 0.053). In their study, DR2
was not resolved into DRB1*15 and 16 subtypes. These
reports suggest that HLA-DRB1*15 may show different
associations with RA in different populations. However, this
could only be confirmed by additional studies on larger
patient and control series in the populations in question.
HLA-DRB1*15 is a relatively common genotype with a fre-
quency varying from 14-46% depending on the ethnic
group.18 The frequency of HLA-DR2 (DR15 and DR16) in
our control group was 34.4% this is a smaller to 38.4% and
33.5% reported earlier by Zafar et al.22 and Hannan et al.23
respectively, in Pakistani populations.  However, Hameed et
al.21 presented lower frequencies (19%) of HLA-DR2 in
their control group of Pakistani origin. HLA-DRB1*08 and
HLA-DRB1*09 were present in very low frequencies (1%)
in Pakistani population.  Out of 91 patients, there were only
2 (one in each group) of these genotypes.  Our observation
of higher frequency of HLA-DRB1*01 in our RA patients is
further supported by an increased frequency of the
DRB1*01-DQB1*06 haplotype in RA patients compared
with healthy controls (P< 0.01).  
MTX is commonly used for the treatment of RA
patients in Pakistan with majority of patients responding to
this treatment.24 Earlier studies have demonstrated an asso-
ciation between the HLA-DR2 and substantial response to
MTX treatment in RA patients.11,15 However, our results
with the exception HLA-DRB1*03 which was more com-
mon among non-responders, demonstrated no apparent
association between distribution of any HLA-DRB1 and
DQB1 genotypes and response to MTX treatment. Similar
findings pertaining to DR2 specificity have also been
reported by Alarcon et al.14 who have shown that neither
HLA-DR2 nor any other HLA-DR specificity is significant-
ly associated with a substantial clinical response to MTX in
patients with RA.  Although, we have noticed higher fre-
quencies of HLA-DRB1*15 and HLA-DQB1*06 in non-
responders compared to responders, this trend was non-sig-
nificant and was in accordance with the findings of Alarcon
et al.14 In a recent study by Criswell et al.25, genetic varia-
tion in the HLA-DRB1 and other loci in close proximity has
been found to be associated with response to treatment of
early RA.  Significantly high frequency of distribution of
HLA-DBR1*03 among non-responders in our study alludes
to the possibility that other loci responsible for MTX metab-
olism might be in linkage disequilibrium with HLA-
DRB1*03 in Pakistani population, making such individuals
non-responsive to MTX treatment.
Conclusion
We report a novel finding that RA susceptibility in
most Pakistani patients is associated with the  HLA-
DRB1*01/XOB1*06 genotype. However, the effectiveness
of HLA-DRB1*01 and DQB1*06 testing as a genetic mark-
er for RA could be established following confirmation of
our findings in a larger study group. HLA-DRB1*03 was
found to be significantly more common among non-respon-
ders to MTX treatment. Our study shows that Pakistani
patients with this genotype are less likely to benefit from
MTX therapy. 
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